CA-PATIENT-SAFETY-MVMT
12.5.2021 14:02:10 CEST | Business Wire | Press release
The Patient Safety Movement Foundation (PSMF) , a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, has selected five individuals for its inaugural Patient Safety Movement Foundation Healthcare Safety Fellowship program. The 12-month, part-time program is focused on providing education and continued development of skills for future healthcare leaders – positioning these stand-out individuals to serve as regional and global leaders in patient safety improvement for years to come.
“We are excited to launch our fellowship program and provide an opportunity to unify and prepare future leaders in patient safety,” said David B. Mayer, MD, CEO of the Patient Safety Movement Foundation. “These individuals have already demonstrated a commitment to improving healthcare, and we look forward to helping them design an individualized education plan that furthers their efforts and collectively helps us in our goal to achieve zero preventable patient deaths by 2030.”
Each of the five fellows will receive guidance from PSMF in designing an actionable plan that is tailored to their background, goals and the specific health needs of their region. In addition, fellows will have opportunities to interact and collaborate with an international network of patient safety and quality mentors, as well as facilitate and lead clinical coaching efforts with hospitals and healthcare organizations across the globe.
This year’s cohort participants include:
-
Luis Ramón Torres Torija Arguelles, MD, MBA
Dr. Luis Torres Torija Arguelles is a physician with a specialty in quality of clinical care from the Tecnológico de Monterrey in Mexico. He currently works as a quality and patient safety coordinator at Hospital Español in Mexico City, Mexico, where he is responsible for the management, design, evaluation, improvement and innovation of clinical care and patient safety processes, incorporating methodologies for continuous improvement and better communication. His efforts to implement all the Patient Safety Movement Foundation’s Actional Patient Safety Solutions have earned his hospital the 5-star Hospital recognition.
-
Carol Gunn, MD
Dr. Carol Gunn attended medical school at UC Davis and completed her internal medicine residency in Portland, Ore., followed by an additional year of training in occupational and environmental medicine at the University of Colorado. In 2007, she opened an independent occupational medicine practice. She thrives on working with individuals and groups advocating for system solutions – whether it be for health, wellness or patient safety.
-
Samar Hassan, PH, MSQ, CPHQ, FISQua
Samar Hassan holds a master’s degree in healthcare quality management and is a registered pharmacist and certified healthcare quality professional with the National Association for Healthcare Quality (NAHQ). In addition, Hassan has worked with the Health Care Accreditation Council (HCAC) in Jordan and the region’s quality improvement and patient safety institution since 2018, where she has been involved in the design, implementation and evaluation of standards for quality and patient safety across health and social care institutions. She has also participated and supported HCAC's advocacy and public awareness programs to synthesize professionals, the public and decision makers on adopting and implementing quality improvement approaches.
-
Elizabeth Namugaya Igaga, MD
Dr. Elizabeth Namugaya Igaga attended Makerere University in Kampala, Uganda, for medical school, as well as her master’s degree in anesthesia and critical care. She is currently doing her clinical practice at the Uganda Heart Institute. Igaga’s interest in patient safety was sparked after multiple firsthand experiences during residency that resulted in near misses or catastrophic outcomes. Since then, she has been passionate about fostering and building a culture of safety in perioperative care in Uganda.
-
Ebikapaye Okoyen, MD, MBBS, MBA, MHPM, FISQua
Dr. Ebikapaye Okoyen works in the Ministry of Health in Yenagoa, Nigeria, as the deputy director and state program manager for Saving One Million Lives Program for Results (SOML PforR) – a World Bank-funded, results-based program financing maternal and child health and nutrition aimed at improving quantity and quality of service. He is a fellow and member of several professional associations including the Nigerian Medical Association, the Society for Quality in Healthcare in Nigeria (SQHN) and is a certified SQHN Health Facility Surveyor with a specialist certificate on the Fundamentals of External Evaluation Surveying from the International Society for Quality in Healthcare (ISQua). He has also published papers in health services research.
To learn more about the Patient Safety Movement Foundation Healthcare Safety Fellowship, visit: https://patient.sm/PR-Fellowship .
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die unnecessarily in U.S. hospitals, with more than three million deaths globally, as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero preventable patient harm and death. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005327/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Quantum Computer Goes Live at Supercomputing Center CINECA in Italy, Boosting National Compute Infrastructure and Research11.6.2026 14:50:00 CEST | Press release
The system will enable advanced applications in optimization, simulation, and machine learning. IQM Radiance quantum computer, featuring a 54-qubit processing unit. The system is being integrated into Leonardo, one of the world's fastest supercomputers. This is the second IQM quantum computer to be operational in Italy. The Italian Research Centre on High Performance Computing, Big Data, and Quantum Computing (ICSC) today inaugurated the IQM Radiance 54 quantum computer at CINECA, one of Europe's leading supercomputing centers, enabling advanced applications in optimization, simulation, and machine learning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611898215/en/ The moment Italy's second IQM quantum computer went live at CINECA in Bologna. IQM has previously announced its ongoing business combination with Real Asset Acquisition Corp (Nasdaq: RAAQ), which will result in IQM becoming a public company in mid-2026. The
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
